Iovance IOVA 深 沪
等待开盘 10-06 09:30:00 美东时间
14.15
-0.065
-0.46%
华盛通- 最 高15.30
- 今 开14.03
- 成交量 1159.88万股
- 最 低 7.66
- 昨 收 14.215
- 总市值 222.16万
- 52周最高 15.30
- 市盈率 静 --
- 换手率 7387.75%
- 52周最低 1.76
- 委 比 -52.78%
- 总股本 0.00亿
- 历史最高 54.208
- 量 比 0.42
- 振 幅 53.75%
- 历史最低 1.10
- 每 手 1
- 风险率 2.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
09-30 01:08
STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside
Stifel upgraded STAAR Surgical to Buy, while raising its price target, citing China momentum, EVO+ mix and upside to 2026-27 estimates.
09-30 00:01
Crude Oil Down 1%; US Job Openings Fall In August
U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
09-30 00:01
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
2025-11-08 02:04
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
盘前异动｜英特尔涨超6%，AEye涨超15%，Iovance飙升20%，Palo Alto Networks绩后涨超5%
8月19日，美股三大股指期货下跌，截止发稿，道指期货跌0.10%，纳指期货跌0.09%，标普500指数期货跌0.12%。 英特尔盘前涨超6%，软银集团与...
2025-08-19 16:06
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics授予58名新员工312,660股股票期权，行权价1.98美元，期权在三年内vest。
2025-06-23 20:05
Iovance Biotherapeutics to Present at Upcoming Conference
Iovance Biotherapeutics' senior leadership will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 11, 2025 at 1:20 p.m. ET in Miami, FL. The company focuses on developing polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, with Amtagvi® being the first FDA-approved T cell therapy for solid tumors.
2025-06-10 12:45
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
Iovance Biotherapeutics reported five-year results from its Phase 2 trial of Amtagvi, a TIL therapy for advanced melanoma. The study showed a median overall survival of 13.9 months, 19.7% five-year survival rate, and 31.4% objective response rate. No new adverse events were reported. Amtagvi is the first one-time cell therapy for solid tumors.
2025-05-22 21:31
吊打半导体新能源车，CGT即将来临，堪称人类有史以来最大的风口
2025年02月22日 00:30:45 “这是价值事务所的第1792篇原创文章” 很多朋友可能不太清楚，医药行业当下其实正处在一个全新时代的边缘，真的就是边缘...
2025-02-22 00:30
